An educational experiment in primary care in Sweden: Improving the management of hypercholesterolaernic patients at risk

European Journal of General Practice

Volumn 3, Issue 3, 1997, Pages 96-102

  Wahlström, Rolf ^a   Diwan, Vinod ^a   Tomson, Göran ^a   Oké, Thimothy ^b   Beermann, Björn ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 37949039748     PISSN: 13814788     EISSN: 17511402     Source Type: Journal    
DOI: 10.3109/13814789709160335     Document Type: Article

References (39)

1. Raisch DW. A model of methods for influencing prescribing: Part I. A review of prescribing models, persuasion theories, and administrative and educational methods. Part II. A review of educational methods, theories of human inference, and delineation of the model. DICP. Ann Pharmacother 1990;24417-541.
2. Soumerai SB, McLaughlin TJ, Avorn J. Improving drug prescribing in primary care: a critical analysis of the experimental literature. Mil- bank Q 1989;67:268-317. (Pubitemid 20278773)
3. Buntinx F, Winkens R, Grol R, Knotmerus JA. Influencing diagnostic and preventive performances in ambulatory care by feedback and reminders. A review. Fum Pruct 1993;11:219-28. (Pubitemid 23210388)
4. Grimshaw JM, Russel IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993;342:1317-22 (Pubitemid 23345178)
5. Kanouse DE, Jacoby I. When does information change practitioners' behavior? IntJ Tech Assessment Health Cure 1988;4:27-33.
6. Lomas J. Words without action? The production, dissemination, and impact of consensus recommendations. In: Omenn GS, Fielding JE, Lave LE, Editors. Annual review of public health. Palo Alto: Annual Review Inc, 1991.
7. Denig P, Haaijer-Ruskamp FM, Zijsling DH. Impact of a drug bulletin on the knowledge, perception of drug utility, and prescribing behavior of physicians. DICP. Ann Pharmacother 199094:87-92.
8. Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah WJ.. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med 1989;321:1306-11 (Pubitemid 19267218)
9. Haijer-Ruskamp FM, Denig P. New approaches to influencing physicians' drug choices: The practice-based strategy. In: Davis P, editor. Contested ground. Oxford: Oxford University Press, 1996.
10. Manning PR, Lee PV, Clintworth WA, Denson TA, Oppenheimer PR, Gilman NJ. Changing prescribing practices through individual continuing education. JAMA 1986;256230-2.
11. Soumerai SB, Avorn J. Principles of educational outreach ('academic detailing') to improve clinical decision making. JAMA 1990;263(4):549-56 (Pubitemid 20030263)
12. Avorn J, Soumerai SB. Improving drug therapy decisions through educational outreach: a randomised controlled trial of academically based 'detailing'. N Engl J Med 1983;308:1457-63. (Pubitemid 13103447)
13. Hjermann I, Velve Byre K, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo study group of a randomised trial in healthy men. Lancet 1981;Dec 12:1303-10. (Pubitemid 12180386)
14. Lipids Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. 11. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984952351-73.
15. Frick MH, Elo 0, Haapa K, et al. Helsinki Heart Study: Primary-pre-vention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N EnglJ Med 1987;317:1237-45. (Pubitemid 17147964)
16. Strandberg K, Beermann B, Lonnerholm G. Treatment of hyperlipidemia. Uppsala: National Board of Health and Welfare. Drug Information Committee, 1989.
17. Wahlstrom R, Tomson G, Diwan VK, Beermann B, Sterky G. Hyperlipidaemia in primary care - A randomized controlled trial on treatment information in Sweden: Design and methodology. Pharmacoepid Drug Safety 1995;4:75-90.
18. Diwan V K, Eriksson B, Sterky G, Tomson G. Randomization by group in studying the effect of drug information in primary care. Fnt J Epid 1992;21:124-30
19. Wyatt J. Evaluating medical expert systems: What to test and how? Med Inform 199O;lS:lll-5.
20. Siege1 S, Castellan NJ. Nonparametric statistics for the behavioral sciences. New York: McGraw-Hill, 1988.
21. Romm FJ, Putnam SM. The validity of the medical record. Med Care 1981;12(3):310-5 (Pubitemid 11067390)
22. Gerbert B, Hargreaves WA. Measuring physician behaviour. Med Care 1986;24(9):838-47.
23. Rethans JJ, Westin S, Hays R. Methods for quality assessment in general practice. Fam Pract 1996;13:468-6.
24. Diwan VK, Wahlstrom R, Tomson G, Beermann B, Sterky G, Eriksson B. Effects of 'group detailing' on the prescribing of lipid-lower- ing drugs: a randomised controlled trial in Swedish primary care. J Clin Epid 1995;48(5):705-11.
25. Smith GD, Pekkanen J. Should there be a moratorium on the use of cholesterol-lowering drugs? Br Med J 1992;304:431-4
26. Larsson A, Werko L, Enkvist C. Cholesterol-lowering in women. Wrong therapy after drug information (in Swedish). Lijkartidningen 1994;91:4280-1
27. Beermann B, Madsen S, Strandberg K, Waerstad A, Westbye 0. Treatment of hyperlipidaemia. Uppsala: Medical Products Agency, 1996.
28. Troein M, Arneson T, Ristam L, Pirie PL, Selander S, Luepker RV. Reported treatment of hypercholesterolaemia by family physicians in Sweden and Minnesota. Am J Prev Med 1995;11:324-8.
29. Dahlgren LO, Diwan VK, Tomson G, Wahlstrom R. On the variation in conceptions among primary care physicians regarding hypercholesterolaemia: A phenomenographic analysis. Scand J Prim Health Carel 992;103 16-20.
30. Lip GYH. lntracardiac thrombus formation in cardiac impairment: Investigation and the Role of Anticoagulant Therapy. Postgrad Med J 1996;72:731-8
31. ASPECT Study Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503.
32. Francis CM, Caruana L, Kearney P, Love M, Sutherland GR, Starkey IR, et al. Open access echocardiography in management of heart failure in the community. Br Med J 1995;310:634-6.
33. Lip GYH, Zarifis J. Diastolic dysfunction. Eur ] Zntern Med 1995;6145-54
34. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991;12:315-21
35. Davie AP, Francis CM, Love MP, Caruana L. Starkey IR, Shaw TRD, et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. Br Med J 1996;312:222. (Pubitemid 26031435)
36. Mair FS, Bundred PE. The diagnosis and management of heart failure: GP options. Br] Curdiol1996;3:121-5.
37. Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31
38. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomised Amlodipine Survival Evaluation Study Group. N Engl J Med 1996;335:1107-14. (Pubitemid 26330964)
39. Cohn JN, Ziesche SM, Loss LE, Anderson GF, and the V-Hem study group. Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: Results of VHeFT 111. Circulation 1995;92:1-143 (abstract).